Docetaxel-induced extravasation injury: A report of three cases

Journal of Oncology Pharmacy Practice

Volumn 6, Issue 3, 2000, Pages 122-125

  Harrison, Bruce R ^a,b   Ketts, Jennifer R ^c   Schultz, Michelle z ^a,d   Yackzan, Susan ^e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ST LOUIS COLLEGE OF PHARMACY   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

Author keywords

chemotherapy; docetaxel; Extravasation; vesicant

Indexed keywords

EID: 84990378629     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/107815520000600306     Document Type: Article

References (17)

1. Larson DL. Treatment of tissue extravasation by antitumor agents. Cancer. 1982; 49: 1796-1799.
2. Laughlin RA, Landeen JM, Habal MB. The management of inadvertent subcutaneous Adriamycin infiltration. Am J Surg. 1979; 137: 408-412.
3. Barlock AL, Howser DM, Hubbard SM. Nursing management of Adriamycin extravasation. Am J Nurs. 1979; 137: 94-96.
4. Door RT. Managing extravasations of vesicant chemotherapy drugs. In: Lipp H, ed. Anticancer Drug Toxicity: Prevention, Management, and Clinical Pharmacokinetics. New York: Marcel Dekker; 1999: 279-318.
5. Goodman M, Stewart I, Lydon J, Blendowski C, Barnicle M. Use caution when managing paclitaxel and taxotere infiltrations. Oncol Nurs Forum. 1996; 23: 541-542.
6. Bertelli G, Cafferata M, Ardizzoni A, Gozza A, Rosso R. Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer. 1997; 79: 2267-2268.
7. Bicher A, Levenback C, Burke T, Mitchell M, Warner D, DeJesus Y, et al. Infusion site soft-tissue injury after paclitaxel administration. Cancer. 1995; 76: 116-120.
8. Ajani J, Dodd L, Daugherty K, Warkentine D, Ilson D. Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course. J Natl Cancer Inst. 1994; 86: 51-53.
9. Herrington JD, Figueroa JA. Severe necrosis due to paclitaxel extravasation. Pharmacotherapy. 1997; 17: 163-165.
10. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989; 111: 273-279.
11. Rowinsky EK, Chaudhry V, Forastiere AA, et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose limiting. J Clin Oncol. 1993; 11: 2010-2020.
12. Stein ME, Drumea K, Abu-Rasmi R, et al. Taxolinduced cellulitis after extravasation: a rarely reported event. Am J Clin Oncol. 1997; 20: 540.
13. Meehan J, Sporn J. Case report of taxol administration via central vein producing a recall reaction at a site of prior taxol extravasation. J Natl Cancer Inst. 1994; 86: 1250-1251.
14. Hidalgo M, Benito J, Colomer R, Paz-Ares L. Recall reaction of a severe local peripheral neuropathy after paclitaxel extravasation. J Natl Cancer Inst. 1996; 88: 1320.
15. Shapiro J, Richardson GE. Paclitaxel-induced “recall” soft tissue injury occurring at the site of previous extravasation with subsequent intravenous treatment in a different limb. J Clin Oncol. 1994; 12: 2237-2238.
16. Dorr R, Sneed K, Liddil J. Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer. 1996; 78: 152-156.
17. Powell L. Cancer Chemotherapy Guidelines and Recommendations for Practice. Oncology Nursing Press; 1996.